Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis.
Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis.
复制标题
与学术医学中心的抗体反应变化有关BNT162B2 COVID-19的抗体反应的变化相关的人口和临床特征：纵向队列分析。
DOI：
10.1136/bmjopen-2021-059994
复制
发表时间：
2022-05-24
期刊：
影响因子：
2.9
通讯作者：
Sobhani, Kimia
中科院分区：
文献类型：
--
作者：
Ebinger, Joseph E.;Joung, Sandy;Liu, Yunxian;Wu, Min;Weber, Brittany;Claggett, Brian;Botting, Patrick G.;Sun, Nancy;Driver, Matthew;Kao, Yu Hung;Khuu, Briana;Wynter, Timothy;Nguyen, Trevor-Trung;Alotaibi, Mona;Prostko, John C.;Frias, Edwin C.;Stewart, James L.;Goodridge, Helen S.;Chen, Peter;Jordan, Stanley C.;Jain, Mohit;Sharma, Sonia;Fert-Bober, Justyna;Van Eyk, Jennifer E.;Minissian, Margo B.;Arditi, Moshe;Melmed, Gil Y.;Braun, Jonathan G.;McGovern, Dermot P. B.;Cheng, Susan;Sobhani, Kimia
我们试图了解在完成两剂BNT162b2疫苗接种后，与纵向抗体反应变化相关的人口统计学和临床因素。这项研究是一项为期10个月的纵向队列研究，研究对象是医护人员，使用混合线性模型连续测量抗峰蛋白Ig G(S)抗体水平，以检验其与参与者特征的关系。位于美国南加州的大型多站点学术医疗中心。共有843名医护人员符合纳入标准，包括完成BNT162b2疫苗的初始两剂疗程，完整的临床病史和至少两个用于分析的血液样本。患者平均年龄(45±13)岁，女性占70%，有SARS-CoV-2感染史者占7%。在初次接种两剂疫苗后10个月，99.6%的人疫苗诱导的免疫球蛋白-S水平保持在阳性范围内。既往SARS冠状病毒感染是疫苗接种后持续升高的主要相关因素(偏R2=0.133)，免疫后血清免疫球蛋白-S水平(SD)为1.74±0.11SD(p<；0.001)。女性(Beta0.27±0.06，p<；0.001)、年轻(0.01±0.00，p<；0.001)和无高血压(0.17±0.08，p=0.003)也与持续较高的免疫球蛋白-S反应有关。值得注意的是，既往感染SARS-CoV-2的个体增加了性别(男性为0.42，p=0.08)和修正了与高血压的关联(1.17，p=0.001)，因此，感染幼稚的高血压患者的−-S水平持续较低，而既往感染的高血压患者的Ig G-S水平较高，并随着时间的推移保持上升。虽然大多数成年人在首次接种疫苗后10个月内抗体反应仍保持在阳性范围内，但抗体水平持续较高的决定因素包括既往感染过SARS-CoV-2、女性、较年轻的年龄和没有高血压。纵向抗体反应的某些决定因素似乎明显受到先前感染状态的影响。这些发现为可能影响自然感染和疫苗接种所产生的“混合”免疫的因素提供了洞察力。
We sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination. This study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics. A large, multisite academic medical centre in Southern California, USA. A total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection. Vaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R2=0.133), with a 1.74±0.11 SD higher IgG-S response (p<0.001). Female sex (beta 0.27±0.06, p<0.001), younger age (0.01±0.00, p<0.001) and absence of hypertension (0.17±0.08, p=0.003) were also associated with persistently higher IgG-S responses. Notably, prior SARS-CoV-2 infection augmented the associations of sex (−0.42 for male sex, p=0.08) and modified the associations of hypertension (1.17, p=0.001), such that infection-naïve individuals with hypertension had persistently lower IgG-S levels whereas prior infected individuals with hypertension exhibited higher IgG-S levels that remained augmented over time. While the IgG-S antibody response remains in the positive range for up to 10 months following initial mRNA vaccination in most adults, determinants of sustained higher antibody levels include prior SARS-CoV-2 infection, female sex, younger age and absence of hypertension. Certain determinants of the longitudinal antibody response appear significantly modified by prior infection status. These findings offer insights regarding factors that may influence the ‘hybrid’ immunity conferred by natural infection combined with vaccination.
登录
查看更多内容
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
影响因子：
4.2
作者：
Young BE;Mak TM;Ang LW;Sadarangani S;Ho HJ;Wilder-Smith A;Barkham T;Chen M
通讯作者：
Chen M
影响因子：
64.8
作者：
Collier DA;Ferreira IATM;Kotagiri P;Datir RP;Lim EY;Touizer E;Meng B;Abdullahi A;CITIID-NIHR BioResource COVID-19 Collaboration;Elmer A;Kingston N;Graves B;Le Gresley E;Caputo D;Bergamaschi L;Smith KGC;Bradley JR;Ceron-Gutierrez L;Cortes-Acevedo P;Barcenas-Morales G;Linterman MA;McCoy LE;Davis C;Thomson E;Lyons PA;McKinney E;Doffinger R;Wills M;Gupta RK
通讯作者：
Gupta RK
影响因子：
64.8
作者：
Cho A;Muecksch F;Schaefer-Babajew D;Wang Z;Finkin S;Gaebler C;Ramos V;Cipolla M;Mendoza P;Agudelo M;Bednarski E;DaSilva J;Shimeliovich I;Dizon J;Daga M;Millard KG;Turroja M;Schmidt F;Zhang F;Tanfous TB;Jankovic M;Oliveria TY;Gazumyan A;Caskey M;Bieniasz PD;Hatziioannou T;Nussenzweig MC
通讯作者：
Nussenzweig MC